RetaCalc
Protocol library
SingleApproved OtherRegulatory LabelModerate confidenceSourced

Melanotan 1

An alpha-MSH analogue best anchored to afamelanotide evidence. The authorised medicine is a 16 mg controlled-release implant, not a reconstituted research vial.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Regulatory LabelControlled-release implantEvery 60 days
Adults with erythropoietic protoporphyria

A 16 mg subcutaneous controlled-release implant every 60 days

The pivotal trials and European product information concern a professionally inserted implant, not a reconstituted vial.

View source

Evidence summary

An alpha-MSH analogue best anchored to afamelanotide evidence. The authorised medicine is a 16 mg controlled-release implant, not a reconstituted research vial.

Protocol basis

The strongest protocol is the authorised afamelanotide implant schedule for erythropoietic protoporphyria. It establishes a clinical formulation and interval but does not transfer to powder sold under the Melanotan 1 name.

What remains uncertain

Identity, release kinetics, sterility and exposure from a reconstituted vial are not established by the implant literature.

Warnings and contraindications

The authorised afamelanotide product is a controlled-release implant administered by trained clinicians for a specific rare disease.
A lyophilised product sold as Melanotan 1 is not interchangeable with the authorised implant.
Skin pigmentation can obscure changes in moles; specialist skin monitoring is part of the authorised context.